iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials
June 08, 2022 02:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Presents Positive Consistent Results for MINIject® Across Three International Glaucoma Trials Analysis provides further validation of MINIject®’s meaningful and...
Ophthalmic Devices Global Market Report 2022: OCT Scanners Dominated the Product Segment with 23% Revenue Share in 2021
May 27, 2022 06:58 ET
|
Research and Markets
Dublin, May 27, 2022 (GLOBE NEWSWIRE) -- The "Ophthalmic Devices Market Analysis by Product (Optical Coherence Tomography, Ophthalmic Ultrasound), by Application (Cataract, Glaucoma), by End Use...
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 10, 2022 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
April 27, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Insights on the Vision Care Global Market to 2027 - by Product Type, Distribution Channel and Region
April 21, 2022 08:13 ET
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's...
Graybug Vision Appoints Dirk Sauer to Board of Directors
April 13, 2022 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
March 30, 2022 07:15 ET
|
Graybug Vision, Inc.
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal gene therapy...
Global Contact Lenses Markets, 2022-2027 - Introduction of Hi-Tech Contact Lenses / Increasing Use of Silicone Hydrogel Contact Lenses / High Consumer Preference for Premium Cosmetic Lenses
March 28, 2022 05:23 ET
|
Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Contact Lenses Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The contact lenses market...
iSTAR Medical Continues Market Expansion with First MINIject® Surgeries in the UK
March 28, 2022 02:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Continues Market Expansion with First MINIject® Surgeries in the UK UK patients and surgeons now able to benefit from the only commercially available MIGS device...
Graybug Vision to Host Virtual R&D Day on March 30, 2022
March 21, 2022 16:30 ET
|
Graybug Vision, Inc.
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...